Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Silvia Girotti
Observed names:
Girotti, S.,
Girotti, Silvia
Institution:
University of Verona
Observed institution:
University of Verona
ORCID:
0000-0002-0228-9421
Observed ORCID:
0000-0002-0228-9421
OpenAlex ID:
A5002688058
The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis
2022
·
Enrico Costa
, Silvia Girotti
, et al.
·
Orphanet Journal of Rare Diseases
·
60
PDF
Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European Union
2024
·
Enrico Costa
, Silvia Girotti
, et al.
·
Journal of Cystic Fibrosis
·
9
Traits, trends and hits of orphan drug designations in cystic fibrosis
2023
·
Enrico Costa
, Silvia Girotti
, et al.
·
Journal of Cystic Fibrosis
·
7
PDF
Timing and rate of reimbursement for cystic fibrosis modulator therapies in EU countries
2026
·
Enrico Costa
, Silvia Girotti
, et al.
·
Journal of Cystic Fibrosis
Comparison of Different NLP Systems to Extract Adverse Drug Reaction Information from the Medicinal Product Information
2024
·
Girotti, S.
, Cicala, G.
, et al.
·
HAL
Show more works
View as search
Works count:
8
Citation count:
76
H-index:
3
I10-index:
1
Year
Topic
Type